BCYC

BCYC

USD

Bicycle Therapeutics plc American Depositary Shares

$6.870-0.160 (-2.276%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ühendkuningriik

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$7.030

Kõrge

$7.335

Madal

$6.850

Maht

0.42M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

476.6M

Tööstusharu

Biotehnoloogia

Riik

United Kingdom

Kauplemisstatistika

Keskmine maht

0.28M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $6.1Praegune $6.870Kõrge $25.385

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 4. nov 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

BCYC Analysis: Bicycle Therapeutics at Crossroads - Caution Advised Amid Mixed Signals

Recent Price Action & Patterns

  • Volatile swings: Shares dropped sharply to $7.26 (Nov 3) from $8.07 close, marking 10% single-day decline on heavy volume (399k vs 277k avg)
  • Pattern context: Failed breakout attempt above $9 in early October now tests August support near $7.25
  • Volume tells: 3x average volume on down days signals distribution pressure outweighing accumulation

Conflicting Analyst Views

  • Bull case: Citizens upgraded to $12 target (Oct 31) citing pipeline potential
  • Bear case: RBC downgraded same day to $11, cutting previous $27 target by 60%
  • Market reaction: Stock fell 10% post-announcement despite "neutral" sentiment designation

Fundamental Considerations

diff

  • Strong growth metrics: 338% revenue growth YoY
  • Debt concerns: 1.08 debt-to-equity ratio exceeds industry comfort levels ! Valuation disconnect: Negative P/E (-2.05) suggests market pricing in speculative outcomes

Technical Positioning

  • Critical support: $7.25 level held twice in August - breach could trigger algorithmic selling
  • Contradictory signals:
  • MACD suggests near-term bullish crossover
  • DMI indicates weakening momentum (ADX 12.1)
  • Volume reality check: Recent distribution days negate earlier accumulation signals

Strategic Perspective

Immediate term (1-3 days):

  • Monitor $7.25 like hawk - breakdown could accelerate to $6.75-$7.00 zone
  • Any rebound above $7.50 needs confirmation volume (>300k shares)

Entry considerations:

  • Aggressive: Scale-in near $7.30 if volume dries up (<150k/hour)
  • Conservative: Wait for reclaim of $7.75 with >250k volume confirmation

Risk management imperative:

  • Stop loss: $7.20 (below Nov 3 low)
  • Position sizing: Half normal allocation given sector volatility

Final Assessment

Bicycle Therapeutics presents classic biotech dichotomy - compelling science vs. financial reality. The violent reaction to mixed analyst calls suggests traders lack conviction. While AI models project recovery, current price action demands respect for downside risk. Only suitable for risk-tolerant investors with 6+ month horizon.

Disclosure: This analysis observes historical patterns and market conditions as of November 2025. All investments carry risk of loss. Consult a financial advisor before making investment decisions.

Seotud uudised

Analyst Upgrades

Citizens Maintains Market Outperform on Bicycle Therapeutics, Raises Price Target to $12

Citizens analyst Reni Benjamin maintains Bicycle Therapeutics with a Market Outperform and raises the price target from $10 to $12.

Vaata rohkem
Citizens Maintains Market Outperform on Bicycle Therapeutics, Raises Price Target to $12
Analyst Upgrades

RBC Capital Downgrades Bicycle Therapeutics to Sector Perform, Lowers Price Target to $11

RBC Capital analyst Leonid Timashev downgrades Bicycle Therapeutics from Outperform to Sector Perform and lowers the price target from $27 to $11.

Vaata rohkem
RBC Capital Downgrades Bicycle Therapeutics to Sector Perform, Lowers Price Target to $11

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 5. nov 2025, 01:22

LangevNeutraalneTõusev

66.2% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
VäärtusKasv
Kauplemisjuhend

Sisenemispunkt

$6.91

Võta kasum

$7.37

Peata kahjum

$6.18

Põhitegurid

DMI näitab langustrendi (ADX:21.2, +DI:10.9, -DI:17.2), mis viitab ettevaatlikkusele
Praegune hind on tugitasemele ($6.90) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 3.4x keskmisest (3,983), mis viitab äärmiselt tugevale ostusurvele
MACD -0.0335 on signaalijoone -0.0302 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.